摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-苯基甲氧基苯基)N-(4-氟苯基)氨基甲酸酯 | 195140-92-2

中文名称
(4-苯基甲氧基苯基)N-(4-氟苯基)氨基甲酸酯
中文别名
——
英文名称
4-fluorophenylcarbamic acid 4-benzyloxyphenyl ester
英文别名
Carbamic acid, (4-fluorophenyl)-, 4-(phenylmethoxy)phenyl ester;(4-phenylmethoxyphenyl) N-(4-fluorophenyl)carbamate
(4-苯基甲氧基苯基)N-(4-氟苯基)氨基甲酸酯化学式
CAS
195140-92-2
化学式
C20H16FNO3
mdl
——
分子量
337.35
InChiKey
XYUDDOIIYRPZLT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    25
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    47.6
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • Modulation of anxiety through blockade of anandamide hydrolysis
    申请人:The Regents of the University of California
    公开号:US20040127518A1
    公开(公告)日:2004-07-01
    Fatty acid amide hydrolase inhibitors of the Formula: 1 are provided wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula I and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.
    本发明提供了公式1中X为NH,CH2,O或S;Q为O或S;Z为O或N;R为从取代或未取代芳基;取代或未取代联苯基;取代或未取代萘基;取代或未取代苯基;取代或未取代三苯基基;取代或未取代环烷基,杂环芳基或烷基中选择的芳香基;R1和R2分别独立地选择从H,取代或未取代烷基,取代或未取代杂环烷基和取代或未取代苯基,取代或未取代联苯基,取代或未取代芳基和取代或未取代杂环芳基的群中选择;但是如果Z为O,则R1和R2中的一个不存在,如果Z为N,则R1和R2可以选择性地一起形成取代或未取代的N-杂环或取代或未取代的杂环芳基,与它们各自连接的N原子。本发明还提供了包括公式I中化合物的制药组合物以及使用它们来抑制FAAH和/或治疗食欲障碍,青光眼,疼痛,失眠和神经心理障碍,包括焦虑症,癫痫和抑郁症的方法。
  • MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS
    申请人:Piomelli Daniele
    公开号:US20120010283A1
    公开(公告)日:2012-01-12
    Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula I and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.
    提供了公式为的脂肪酸酰胺水解酶抑制剂:其中X为NH,CH2,O或S;Q为O或S;Z为O或N;R为从取代或未取代芳基;取代或未取代联苯基;取代或未取代萘基;取代或未取代苯基;取代或未取代三苯基基;取代或未取代环烷基,杂环芳基或烷基中选择的芳香基;R1和R2分别选择自H,取代或未取代烷基,取代或未取代杂环烷基,取代或未取代苯基,取代或未取代联苯基,取代或未取代芳基和取代或未取代杂环芳基的群中;但是如果Z为O,则R1和R2中的一个不存在,如果Z为N,则可选地将R1和R2结合在一起形成取代或未取代的N-杂环或取代或未取代的杂环芳基,与它们各自连接的N原子。提供了包含公式I化合物的制药组合物以及使用它们来抑制FAAH和/或治疗食欲障碍,青光眼,疼痛,失眠以及神经和心理障碍,包括焦虑症,癫痫和抑郁症的方法。
  • EP1558591A4
    申请人:——
    公开号:EP1558591A4
    公开(公告)日:2007-09-12
  • EP1558591B1
    申请人:——
    公开号:EP1558591B1
    公开(公告)日:2014-05-07
  • US7176201B2
    申请人:——
    公开号:US7176201B2
    公开(公告)日:2007-02-13
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐